Primitive, quiescent Ph+ stem cells from CML patients were insensitive to STI571 in vitro, thereby these immature Ph+ progenitor cells can survive, while the overall sensitivity of CML CD34+ progenitor cells to STI571 is mainly determined by cell cycle status [60]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.